EP1699490A2 - Medikament se lipolyse von fettansammlungen - Google Patents

Medikament se lipolyse von fettansammlungen

Info

Publication number
EP1699490A2
EP1699490A2 EP04803773A EP04803773A EP1699490A2 EP 1699490 A2 EP1699490 A2 EP 1699490A2 EP 04803773 A EP04803773 A EP 04803773A EP 04803773 A EP04803773 A EP 04803773A EP 1699490 A2 EP1699490 A2 EP 1699490A2
Authority
EP
European Patent Office
Prior art keywords
fat
use according
acid
phospholipid
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04803773A
Other languages
German (de)
English (en)
French (fr)
Inventor
Peter Boderke
Matthias Gossel
Walter Kamm
Karl-Heinz Nietsch
Rainer Pooth
Juergen Sandow
Joerg Hager
Gerhard Sattler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maria Clementine Martin Klosterfrau Vertriebs GmbH
Kythera Biopharmaceuticals LLC
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of EP1699490A2 publication Critical patent/EP1699490A2/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Definitions

  • Tocopherol or vitamin E is a representative of a group of seven fat-soluble vitamins with an antioxidant effect, it is part of all membranes of animal cells. The most important naturally occurring compound with vitamin E activity is alpha tocopherol.
  • the phospholipid concentration in the medicament is from 0.5% by weight to 30% by weight, preferably from 5% by weight to 25% by weight, in particular from 10% by weight to 20% by weight.
  • the weight ratio of the component supporting fat loss in the preparation is from 0.00001% by weight to 20% by weight, preferably from 0.0001% by weight to 10% by weight, in particular from 0.001% by weight to 1% by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP04803773A 2003-12-22 2004-12-11 Medikament se lipolyse von fettansammlungen Ceased EP1699490A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10361067A DE10361067A1 (de) 2003-12-22 2003-12-22 Medikamentöse Lipolyse von Fettansammlungen
PCT/EP2004/014134 WO2005063169A2 (de) 2003-12-22 2004-12-11 Medikamentöse lipolyse von fettansammlungen

Publications (1)

Publication Number Publication Date
EP1699490A2 true EP1699490A2 (de) 2006-09-13

Family

ID=34673059

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04803773A Ceased EP1699490A2 (de) 2003-12-22 2004-12-11 Medikament se lipolyse von fettansammlungen

Country Status (11)

Country Link
EP (1) EP1699490A2 (ko)
JP (1) JP2007515439A (ko)
KR (1) KR20060121238A (ko)
CN (1) CN1897974A (ko)
AU (1) AU2004308072A1 (ko)
BR (1) BRPI0417932A (ko)
CA (1) CA2551474A1 (ko)
DE (1) DE10361067A1 (ko)
IL (1) IL176026A0 (ko)
MX (1) MXPA06006645A (ko)
WO (1) WO2005063169A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266873B1 (en) * 2017-04-21 2023-12-01 Ami Pharm Co Ltd An injectable preparation for local fat reduction without pain, edema and side effects, and a method for its preparation

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424508B1 (en) * 2004-05-19 2021-05-05 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Use of sodium deoxycholate for the removal of localized fat accumulation
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
DK1845938T3 (da) * 2005-02-08 2019-07-01 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Fremgangsmåder og relaterede sammensætninger til reduktion af fedt og stramning af hud
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
FR2937554B1 (fr) * 2008-10-27 2010-11-12 Yves Crassas Solutions salines aqueuses pour la destruction de tissus graisseux
BRPI1007812B1 (pt) * 2009-03-02 2017-09-26 Doris Maria Hexsel Lipoatrofia cosmetic medicinal
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
ES2627403T3 (es) 2009-08-25 2017-07-28 Medrx Co., Ltd. Composición transdérmica de fosfatidilcolina y método para producir la misma
DE102010028365A1 (de) 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
CA2842177C (en) * 2011-08-23 2016-07-19 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
RU2016141131A (ru) * 2014-03-21 2018-04-23 Нестек С.А. Введение витамина b2 матери для профилактики повышенной тучности, избыточного веса или ожирения у потомства
KR102093872B1 (ko) * 2017-07-03 2020-03-27 진호성 지방제거용 주사제 조성물 및 이의 제조방법
JP6356329B2 (ja) * 2017-09-27 2018-07-11 キテラ バイオファーマシューティカルズ，インコーポレイテッド デオキシコール酸およびその塩類の製剤
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
CN110302082A (zh) * 2018-03-27 2019-10-08 上海同柏生物科技有限公司 用于减少身体脂肪沉积的技术及组合物制剂与应用
CN109674696A (zh) * 2018-03-27 2019-04-26 上海同柏生物科技有限公司 一种用于腹部脂肪降解技术及其制剂与应用
JP2021186680A (ja) 2020-06-01 2021-12-13 コスメディ製薬株式会社 美容用マイクロニードルアレイ
WO2022019187A1 (ja) * 2020-07-20 2022-01-27 コスメディ製薬株式会社 美容用外用剤及び化粧料
KR102513115B1 (ko) * 2020-12-18 2023-03-22 주식회사 레시텍 리토콜릭산을 포함하는 국소지방 감소용 조성물
KR102691705B1 (ko) * 2021-10-25 2024-08-06 주식회사 지엘케이인터내셔날 지방 분해용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041919A2 (de) * 2003-10-24 2005-05-12 Sanofi-Aventis Deutschland Gmbh Medikamentöse gezielte lokale lipolyse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041919A2 (de) * 2003-10-24 2005-05-12 Sanofi-Aventis Deutschland Gmbh Medikamentöse gezielte lokale lipolyse

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266873B1 (en) * 2017-04-21 2023-12-01 Ami Pharm Co Ltd An injectable preparation for local fat reduction without pain, edema and side effects, and a method for its preparation
IL266873B2 (en) * 2017-04-21 2024-04-01 Ami Pharm Co Ltd An injectable preparation for local fat reduction without pain, edema and side effects, and a method for its preparation

Also Published As

Publication number Publication date
DE10361067A1 (de) 2005-07-14
MXPA06006645A (es) 2006-08-31
WO2005063169A2 (de) 2005-07-14
CA2551474A1 (en) 2005-07-14
AU2004308072A1 (en) 2005-07-14
KR20060121238A (ko) 2006-11-28
WO2005063169A3 (de) 2006-05-04
CN1897974A (zh) 2007-01-17
IL176026A0 (en) 2006-10-05
JP2007515439A (ja) 2007-06-14
BRPI0417932A (pt) 2007-04-17

Similar Documents

Publication Publication Date Title
EP1699490A2 (de) Medikament se lipolyse von fettansammlungen
US20100004216A1 (en) Medicinal lipolysis of accumulation of fat
DE69904208T2 (de) Antioxidative mischung bestehend aus acetyl l-carnitin und alpha-liponsäure
US20120329765A1 (en) Medicinal targeted local lipolysis
DE2907778C2 (ko)
EP1684722B1 (de) Medikamentöse gezielte lokale lipolyse
KR100752990B1 (ko) 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
EP2563370B1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
DE60008374T2 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
EP0945136B9 (de) Topisches Arzneimittel mit einem Gehalt an Ciclosporin
US20140113883A1 (en) Therapeutic micro nutrient composition for lipolysis and sclerosis
DE10221194B4 (de) Hyaluronidasehaltiges Hautpflegemittel
EP1064002A1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
WO2008113421A1 (de) Neue pharmazeutische zusammensetzungen für die lipolyse und verfahren zu deren herstellung
DE2401450A1 (de) Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
DE2117762A1 (de) Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung
DE2401453A1 (de) Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen
US20090221528A1 (en) Therapeutic micro nutrient composition for lipolysis and sclerosis
DE60216453T2 (de) Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels
DE202007004776U1 (de) Neue pharmazeutische Zusammensetzungen für die Lipolyse
DE60305592T2 (de) Liposomenhaltiges Mittel zur Behandlung Gefässerkrankungen
EP1492524A1 (de) Vitamin-kombination zum schutz bei chemo- oder/und strahlungstherapie maligner tumoren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20061106

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070122

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERZ PHARMACEUTICALS GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESEL

Owner name: MERZ PHARMACEUTICALS GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESEL

Owner name: KYTHERA BIOPHARMACEUTICALS, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20131121